Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Red Sox great David Ortiz, who frustrated Yankees, honored by New York SenateGOP attorneys general sue Biden administration and California over rules on gasBrewers' Rhys Hoskins leaves game with injury after hitting a secondNo criminal charges in rare liquor probe at Oregon alcohol agency, state report saysTo invest in China is to invest in the future, says L'Oreal executiveReds' TJ Friedl placed on injured list with fractured left thumbDoomsday prepper reveals what it is really like to live offHong Kong calls for respect of its overseasChris Pratt spends Mother's Day with wife Katherine Schwarzenegger and motherWashington's series opener at the Chicago White Sox has been postponed by rain
3.36s , 6605.3125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Stellar Stream news portal